Mannatech (NASDAQ:MTEX) and STADA Arzneimit/AKT o.N. (OTCMKTS:STDAF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.
Institutional & Insider Ownership
16.0% of Mannatech shares are owned by institutional investors. 24.7% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Mannatech and STADA Arzneimit/AKT o.N.’s revenue, earnings per share and valuation.
STADA Arzneimit/AKT o.N. has higher revenue and earnings than Mannatech.
Mannatech pays an annual dividend of $2.00 per share and has a dividend yield of 10.4%. STADA Arzneimit/AKT o.N. does not pay a dividend. Mannatech has increased its dividend for 2 consecutive years.
This is a summary of recent ratings and price targets for Mannatech and STADA Arzneimit/AKT o.N., as provided by MarketBeat.
This table compares Mannatech and STADA Arzneimit/AKT o.N.’s net margins, return on equity and return on assets.
Risk & Volatility
Mannatech has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, STADA Arzneimit/AKT o.N. has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
Mannatech, Incorporated provides wellness solutions. The company develops, markets, and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It markets its products through network marketing channels in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. The company was founded in 1993 and is headquartered in Coppell, Texas.
About STADA Arzneimit/AKT o.N.
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.